Shares of Albireo Pharma Inc (NASDAQ:ALBO) have been given an average recommendation of “Buy” by the eight research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $60.33.
A number of brokerages have recently commented on ALBO. BidaskClub cut shares of Albireo Pharma from a “sell” rating to a “strong sell” rating in a report on Saturday, August 10th. William Blair reiterated a “buy” rating on shares of Albireo Pharma in a research note on Monday, July 15th. Wedbush reiterated an “outperform” rating and issued a $69.00 price target on shares of Albireo Pharma in a research note on Friday, August 9th. ValuEngine upgraded shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $62.00 price target on shares of Albireo Pharma in a research note on Sunday, August 11th.
Shares of ALBO stock traded up $1.21 during mid-day trading on Friday, reaching $23.43. 30,900 shares of the company’s stock traded hands, compared to its average volume of 45,240. Albireo Pharma has a 12 month low of $19.10 and a 12 month high of $38.69. The company has a market cap of $281.87 million, a P/E ratio of -5.95 and a beta of 1.52. The company’s 50-day moving average price is $27.79 and its 200-day moving average price is $30.48.
A number of institutional investors have recently made changes to their positions in the stock. Private Advisors LLC boosted its stake in Albireo Pharma by 3.4% in the 1st quarter. Private Advisors LLC now owns 15,198 shares of the biopharmaceutical company’s stock worth $490,000 after purchasing an additional 506 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Albireo Pharma by 27.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,836 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 614 shares during the period. Hartwell J M Limited Partnership lifted its stake in Albireo Pharma by 8.8% during the 2nd quarter. Hartwell J M Limited Partnership now owns 15,500 shares of the biopharmaceutical company’s stock valued at $500,000 after acquiring an additional 1,250 shares during the period. Alps Advisors Inc. lifted its stake in Albireo Pharma by 4.5% during the 1st quarter. Alps Advisors Inc. now owns 28,912 shares of the biopharmaceutical company’s stock valued at $931,000 after acquiring an additional 1,253 shares during the period. Finally, Aperio Group LLC bought a new position in Albireo Pharma during the 2nd quarter valued at about $42,000. Institutional investors own 70.59% of the company’s stock.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Read More: What is meant by holder of record?
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.